Impact of implant composition of twin-screw extruded lipid implants on the release behavior

International Journal of Pharmaceutics

Volumn 493, Issue 1-2, 2015, Pages 102-110

  Even, Marie Paule ^a   Bobbala, Sharan ^b   Kooi, Kok Liang ^b   Hook, Sarah ^b   Winter, Gerhard ^a   Engert, Julia ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Lipid implants; Ovalbumin; Quil A; Sustained release of antigen; Twin screw extrusion; Vaccine delivery

Indexed keywords

ANTIGEN; CHOLESTEROL; DYNASAN 114; LIPID; OVALBUMIN; PHOSPHATIDYLCHOLINE; QUIL A; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; DRUG IMPLANT; IMMUNOLOGICAL ADJUVANT; QUILLAJA SAPONIN; TRIMYRISTIN; VACCINE;

ARTICLE; COMPRESSION; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG IMPLANT; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INVESTIGATIVE PROCEDURES; LIPID COMPOSITION; LIPOSOMAL DELIVERY; MECHANICAL STRESS; MELTING POINT; PRIORITY JOURNAL; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TEMPERATURE SENSITIVITY; TEMPERATURE STRESS; THERMAL ANALYSIS; THERMOGRAPHY; TWIN SCREW EXTRUSION; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; PHARMACEUTICS;

ADJUVANTS, IMMUNOLOGIC; CALORIMETRY, DIFFERENTIAL SCANNING; CHOLESTEROL; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; DRUG LIBERATION; LECITHINS; LIPIDS; OVALBUMIN; QUILLAJA SAPONINS; TECHNOLOGY, PHARMACEUTICAL; TRIGLYCERIDES; VACCINES;

EID: 84938332736     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.06.052     Document Type: Article

References (35)

1. S. Allababidi, and J.C. Shah Efficacy and pharmacokinetics of site-specific cefazolin delivery using biodegradable implants in the prevention of post-operative wound infections Pharm. Res. 15 2 1998 325 333
2. R. Arnon, and T. Ben-Yedidia Old and new vaccine approaches Int. Immunopharmacol. 3 8 2003 1195 1204 10.1016/s1567-5769(03)00016-x
3. S. Bobbala, A. McDowell, and S. Hook Quantitation of the immunological adjuvants, monophosphoryl lipid A and Quil A in poly (lactic-co-glycolic acid) nanoparticles using high performance liquid chromatography with evaporative light scattering detection J. Chromatogr. B 975 0 2015 45 51 10.1016/j.jchromb.2014.11.006
4. A. Brunner, K. Mader, and A. Gopferich pH and osmotic pressure inside biodegradable microspheres during erosion Pharm. Res. 16 6 1999 847 853
5. S.R. Brych, Y.R. Gokarn, H. Hultgen, R.J. Stevenson, R. Rajan, and M. Matsumura Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation J. Pharm. Sci. 99 2 2010 764 781
6. H. Bunjes, K. Westesen, and M.H.J. Koch Crystallization tendency and polymorphic transitions in triglyceride nanoparticles Int. J. Pharm. 129 1-2 1996 159 173 10.1016/0378-5173(95)04286-5
7. D. Chapman The polymorphism of glycerides Chem. Rev. 62 5 1962 433 456 10.1021/cr60219a003
8. P.H. Demana, N.M. Davies, S. Hook, and T. Rades Quil-A-lipid powder formulations releasing ISCOMs and related colloidal stuctures upon hydration J. Controlled Release 103 1 2005 45 59 10.1016/j.jconrel.2004.11.027
9. M.P. Even, K. Young, G. Winter, S. Hook, and J. Engert In vivo investigation of twin-screw extruded lipid implants for vaccine delivery Eur. J. Pharm. Biopharm 87 2 2014 338 346
10. M.P. Even, K. Young, G. Winter, S. Hook, and J. Engert In vivo ingestigation of twin-screw extruded lipid implants for vaccine delivery Eur. J. Pharm. Biopharm. 87 2 2014 338 346 10.1016/j.ejpb.2014.02.014 Epub 2014 Mar 4
11. W.R. Gombotz, and D.K. Pettit Biodegradable polymers for protein and peptide drug delivery Bioconjugate Chem. 6 4 1995 332 351 10.1021/bc00034a002
12. C. Guse, S. Koennings, F. Kreye, F. Siepmann, A. Goepferich, and J. Siepmann Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms Int. J. Pharm. 314 2 2006 137 144 10.1016/j.ijpharm.2005.08.030
13. C. Guse, S. Koennings, A. Maschke, M. Hacker, C. Becker, S. Schreiner, and A. Goepferich Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids Int. J. Pharm. 314 2 2006 153 160 10.1016/j.ijpharm.2005.12.050
14. A.T. Kamath, B. Mastelic, D. Christensen, A.-F. Rochat, E.M. Agger, D.D. Pinschewer, and C.-A. Siegrist Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses J. Immunol. 188 10 2012 4828 4837 10.4049/jimmunol.1103183
15. G.F.A. Kersten, and D.J.A. Crommelin Liposomes and ISCOMS as vaccine formulations Biochim. Biophys. Acta (BBA) - Rev. Biomembr. 1241 2 1995 117 138 10.1016/0304-4157(95)00002-9
16. S. Koennings, A. Sapin, T. Blunk, P. Menei, and A. Goepferich Towards controlled release of BDNF manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain J. Controlled Release 119 2 2007 163 172 10.1016/j.jconrel.2007.02.005
17. F. Kreye, F. Siepmann, and J. Siepmann Lipid implants as drug delivery systems Expert Opin. Drug Delivery 5 3 2008 291 307 10.1517/17425247.5.3.291
18. F. Kreye, F. Siepmann, J.F. Willart, M. Descamps, and J. Siepmann Drug release mechanisms of cast lipid implants Eur. J. Pharm. Biopharm. 78 3 2011 394 400 10.1016/j.ejpb.2011.02.011
19. F. Kreye, F. Siepmann, A. Zimmer, J.F. Willart, M. Descamps, and J. Siepmann Cast lipid implants for controlled drug delivery: importance of the tempering conditions J. Pharm. Sci. 100 8 2011 3471 3481 10.1002/jps.22574
20. F. Kreye, F. Siepmann, A. Zimmer, J.F. Willart, M. Descamps, and J. Siepmann Controlled release implants based on cast lipid blends Eur. J. Pharm. Sci. 43 1-2 2011 78 83 10.1016/j.ejps.2011.03.013
21. S.A. Lofthouse, M. Kajihara, S. Nagahara, A. Nash, G.J. Barcham, B. Sedgmen, and A. Sano Injectable silicone implants as vaccine delivery vehicles Vaccine 20 13-14 2002 1725 1732 10.1016/S0264-410X(02)00036-1
22. S. Mohl, and G. Winter Continuous release of rh-interferon α-2a from triglyceride matrices J. Controlled Release 97 1 2004 67 78 10.1016/j.jconrel.2004.02.027
23. J. Myschik, F. Eberhardt, T. Rades, and S. Hook Immunostimulatory biodegradable implants containing the adjuvant Quil-A - Part I: physicochemical characterisation J. Drug Target 16 3 2008 213 223 10.1080/10611860701848860
24. J. Myschik, W.T. Mcburney, T. Hennessy, A. Phipps-Green, T. Rades, and S. Hook Immunostimulatory biodegradable implants containing the adjuvant Quil-A - Part II: in vivo evaluation J. Drug Target 16 3 2008 224 232 10.1080/10611860701848886
25. I. Preis, and R.S. Langer A single-step immunization by sustained antigen release J. Immunol. Methods 28 1-2 1979 193 197
26. S.D. Putney, and P.A. Burke Improving protein therapeutics with sustained-release formulations Nat. Biotechnol. 16 2 1998 153 157
27. C.J. Roberts Protein aggregation and its impact on product quality Curr. Opin. Biotechnol. 30 0 2014 211 217 10.1016/j.copbio.2014.08.001
28. A.S. Rosenberg Effects of protein aggregates: an immunologic perspective AAPS J. 8 3 2006 E501 E507
29. A. Rothen-Weinhold, K. Besseghir, Y. De Zelicourt, and R. Gurny Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatin analogue J. Controlled Release 52 1-2 1998 205 213
30. G. Sax, and G. Winter Mechanistic studies on the release of lysozyme from twin-screw extruded lipid implants J. Controlled Release 163 2 2012 187 194 10.1016/j.jconrel.2012.08.025
31. G. Sax, B. Kessler, E. Wolf, and G. Winter In-vivo biodegradation of extruded lipid implants in rabbits J. Controlled Release 163 2 2012 195 202 10.1016/j.jconrel.2012.08.026
32. W. Vogelhuber, E. Magni, A. Gazzaniga, and A. Göpferich Monolithic glyceryl trimyristate matrices for parenteral drug release applications Eur. J. Pharm. Biopharm. 55 1 2003 133 138 10.1016/s0939-6411(02)00137-6
33. W. Vogelhuber, E. Magni, M. Mouro, T. Spruß, C. Guse, A. Gazzaniga, and A. Göpferich Monolithic triglyceride matrices: a controlled-release system for proteins Pharm. Dev. Technol. 8 1 2003 71 79 10.1081/PDT-120017525
34. M. Windbergs, C. Strachan, and P. Kleinebudde Investigating the principles of recrystallization from glyceride melts AAPS PharmSciTech 10 4 2009 1224 1233 10.1208/s12249-009-9311-5
35. Y. Yamagata, K. Iga, and Y. Ogawa Novel sustained-release dosage forms of proteins using polyglycerol esters of fatty acids J. Controlled Release 63 3 2000 319 329 10.1016/s0168-3659(99)00206-0